Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2018-04-06
|
THR-149 |
diabetic macular edema |
preclinical |
Thrombogenics (Belgium) |
Ophtalmological diseases |
2018-04-05
|
Tau Morphomers |
Alzheimer's disease |
1 |
AC Immune (Switzerland) |
Neurodegenerative diseases |
2018-04-04
|
THR-317 |
diabetic macular edema |
2 |
Thrombogenics (Belgium) |
Ophtalmological diseases |
2018-04-04
|
SB-913 (adeno-associated virus serotype 2/6 (rAAV2/6) vectors encoding zinc finger nucleases (ZFNs) and the human iduronate 2-sulfatase (hIDS) gene) |
mucopolysaccharidosis type II (Hunter's syndrome) |
preclinical |
Sangamo Therapeutics (USA - CA) |
Rare diseases - Genetic diseases - Hematological diseases |
2018-04-03
|
sparsentan (RE-021) |
focal segmental glomerulosclerosis (FSGS) |
3 |
Retrophin (USA - CA) |
Rare diseases - Kidney diseases - Renal diseases |
2018-03-29
|
FATE-NK100 (adaptive NK cell therapy) |
ovarian cancer resistant to, or recurrent on, platinum-based treatment |
1 |
Fate Therapeutics (USA - CA) |
Cancer - Oncology |
2018-03-28
|
FPA150 |
advanced or metastatic breast, ovarian, endometrial and bladder cancers |
1 |
Five Prime Therapeutics (USA - CA) |
Cancer - Oncology |
2018-03-26
|
ALX-0061 - vobarilizumab |
systemic lupus erythematosus (SLE) |
2 |
Ablynx (Belgium) AbbVie (USA -IL) |
Autoimmune diseases |
2018-03-26
|
GNbAC1 |
relapsing-remitting multiple sclerosis (RRMS) |
2b |
GeNeuro (Switzerland) |
Autoimmune diseases - Neurodegenerative diseases |
2018-03-22
|
rovalpituzumab tesirine (Rova-T) |
relapsed or refractory delta-like protein 3 (DLL3) expressing small cell lung cancer (SCLC) |
2 |
Stemcentrx (USA - CA), now AbbVie (USA - IL) |
Cancer - Oncology - Rare diseases |
2018-03-19
|
BGS-649 (leflutrozole) |
hypogonadotropic hypogonadism (HH) |
2b |
Mereo Biopharma (UK) |
Endocrine diseases - Hormonal diseases - Metabolic diseases |
2018-03-19
|
ProTmune™ |
prevention of acute graft-versus-host disease (GvHD) |
1-2 |
Fate Therapeutics (USA - CA) |
Transplantation |
2018-03-15
|
alpha-synuclein-PET tracers |
Parkinson's disease |
preclinical |
AC Immune (Switzerland) |
Neurodegenerative diseases |
2018-03-12
|
G100 and pembrolizumab |
follicular lymphoma |
1-2 |
Immune Design (USA - MA) Merck&Co (USA - NJ) |
Cancer - Oncology |
2018-03-12
|
CMB305 (LV305 and G305) - dendritic-cell targeting, lentiviral vector encoding the NY-ESO-1 gene05 |
soft tissue sarcoma |
1-2 |
Immune Design (USA - MA) |
Cancer - Oncology |
2018-03-08
|
IFX-1 |
moderate to severe Hidradenitis Suppurativa (HS) |
2b |
InflaRx (Germany) |
Dermatological diseases - Inflammatory diseases |
2018-03-07
|
DTX301 |
ornithine transcarbamylase deficiency |
1-2 |
Ultragenyx Pharmaceutical (USA - CA) |
Rare diseases - Genetic diseases - Metabolic diseases |
2018-03-03
|
DX-2930 - lanadelumab |
type 1 and type 2 hereditary angioedema (HAE) |
3 |
Dyax (USA - MA), now Shire (UK - USA) |
Rare diseases - Genetic diseases - Hematological diseases |
2018-02-21
|
CAR-Treg manufacturing process |
|
- |
Txcell (France) |
Technology - Services - Autoimmune diseases - Immunological diseases |
2018-02-20
|
FATE-NK100 (adaptive NK cell therapy) |
advanced solid tumors |
1 |
Fate Therapeutics (USA - CA) |
Cancer - Oncology |